Education
About Us
Working with TipRanks
Follow Us
Climb Bio (CLYM)
NASDAQ:CLYM
CLYM Stock Chart & Stats
$2.06
-$0.15(-7.18%)
At close: 4:00 PM EST
$2.06
-$0.15(-7.18%)
Day’s Range― - ―
52-Week Range$1.05 - $5.00
Previous CloseN/A
Volume51.97K
Average Volume (3M)721.78K
Market Cap
$130.78M
Enterprise Value-$258.45K
Total Cash (Recent Filing)$84.70M
Total Debt (Recent Filing)$639.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 18, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding67,764,100
10 Day Avg. Volume1,217,427
30 Day Avg. Volume721,779
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.80
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$9.20Price Target Upside346.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical DataBudoprutug has already demonstrated strong proof-of-concept data in primary membranous nephropathy (pMN), an indication with blockbuster potential on its own.
Financial StabilityThe company ended with significant cash reserves, sufficient to fund operations through 2027, providing financial stability.
Product DevelopmentThe potential of the company’s CD19 antibody, budoprutug, being developed across a range of autoimmune indications supports an Outperform rating.
Bears Say
Clinical TrialsEarly clinical data for budo in primary membranous nephropathy (pMN) have shown positive efficacy and safety.
Market CompetitionClimb Bio in-licensed a novel APRIL antibody, CLYM116, with sweeping functionality and Fc engineering to reduce target-mediated drug disposition (TMDD) and increase the half-life, differentiating it from competitors.
Climb Bio News
CLYM FAQ
What was Climb Bio’s price range in the past 12 months?
Climb Bio lowest stock price was $1.05 and its highest was $5.00 in the past 12 months.
What is Climb Bio’s market cap?
Climb Bio’s market cap is $130.78M.
When is Climb Bio’s upcoming earnings report date?
Climb Bio’s upcoming earnings report date is Nov 18, 2025 which is in 26 days.
How were Climb Bio’s earnings last quarter?
Climb Bio released its earnings results on Aug 12, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.185 by $0.055.
Is Climb Bio overvalued?
According to Wall Street analysts Climb Bio’s price is currently Undervalued.
Does Climb Bio pay dividends?
Climb Bio does not currently pay dividends.
What is Climb Bio’s EPS estimate?
Climb Bio’s EPS estimate is -0.15.
How many shares outstanding does Climb Bio have?
Climb Bio has 67,764,100 shares outstanding.
What happened to Climb Bio’s price movement after its last earnings report?
Climb Bio reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.185. Following the earnings report the stock price went down -2.424%.
Which hedge fund is a major shareholder of Climb Bio?
Currently, no hedge funds are holding shares in CLYM
Climb Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.20 (346.60% Upside)
$9.20 (346.60% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-60.28%
12-Months-Change
Fundamentals
Return on Equity
-22.92%
Trailing 12-Months
Asset Growth
-14.88%
Trailing 12-Months
Company Description
Climb Bio
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
CLYM Stock 12 Month Forecast
Average Price Target
$9.20
▲(346.60% Upside)
Technical Analysis
Agenus
―
TuHURA Biosciences
―
Ovid Therapeutics
―
Cognition Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
8.54% Insiders
2.79% Mutual Funds
61.84% Other Institutional Investors
24.44% Public Companies and Individual Investors
Options Prices
Currently, No data available
---